Oxford Cannabinoid Technologies Achieves Milestone in Phase One Clinical Trial #octp

StockBox

10.8K subscribers

ShareSubscribe

Oxford Cannabinoid Technologies has achieved a significant milestone by successfully administering its lead drug candidate, OCT 461201, in a phase one clinical trial involving healthy volunteers. Focus on establishing safety and tolerability of the drug in preparation for the next phase targeting chemotherapy-induced peripheral neuropathy (CIPN) Dr. Paul Farquhar-Smith, an internationally recognized pain specialist, appointed as an external advisor to provide expertise for developing a first-in-class treatment for CIPN. By Mark Fairbairn